Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Phase I, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms
Study Type: Treatment
Phase: I
NCTID: NCT06313593
Principal Investigator:
Abdulraheem Yacoub
A Phase II Randomized Study of Ruxolitinib vs Prednisone as First-Line Therapy for Chronic Graft vs Host Disease cGVHD Needing Systemic Therapy
Study Type: Treatment
Phase: II
NCTID: NCT06660355
Principal Investigator:
Muhammad Umair Mushtaq
Phase I Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia
Study Type: Treatment
Phase: I
NCTID: NCT06001788
Principal Investigator:
Tara Lin
A Randomized Phase III Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamicin with or without Venetoclax in Children with Relapsed AML
Study Type: Treatment
Phase: III
NCTID: NCT05183035
Principal Investigator:
Kevin Ginn
Phase I study of venetoclax/azacitidine or venetoclax in combination with ziftomenib KO-539 or standard induction cytarabine/daunorubicin 7+3 chemotherapy in combination with ziftomenib for the treatment of patients with acute myeloid leukemia
Study Type: Treatment
Phase: I
NCTID: NCT05735184
Principal Investigator:
Tara Lin
A Phase 2 Study of Inotuzumab Ozogamicin NSC 772518 in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia B-ALL
Study Type: Treatment
Phase: II
NCTID: NCT02981628
Principal Investigator:
Kevin Ginn
A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia AML: A MyeloMATCH Treatment Trial
Study Type: Treatment
Phase: II
NCTID: NCT06317649
Principal Investigator:
Jesus Gonzalez Lugo
A Randomized Phase III Study of Ibrutinib plus Obinutuzumab versus Ibrutinib plus Venetoclax and Obinutuzumab in Untreated Older Patients /= 65 Years of Age with Chronic Lymphocytic Leukemia CLL
Study Type: Treatment
Phase: III
NCTID: NCT03737981
Principal Investigator:
Marc Hoffmann
A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy
Study Type: Supportive Care
Phase: III
NCTID: NCT05602194
Principal Investigator:
Keith August
An Open Label, Single-Center, Pilot Trial of the Combination of Tagraxofusp TAG with Pacritinib PAC in Patients with Intermediate-1 or Higher Myelofibrosis MF, Who Have had Prior Therapy with the Approved JAK1/2 Inhibitors or in Which Therapy with the Approved JAK1/2 Inhibitors is Not Appropriate, Contraindicated or Declined by the Subjects
Study Type: Treatment
Phase: Feasibility/Pilot
NCTID: NCT06414681
Principal Investigator:
Abdulraheem Yacoub